CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 136 enrolled
Drug / intervention
DCVAC/OvCa with Standard of Care +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02107937
NCT02107937Phase 2Completed
CompareCT.gov

A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma

SOTIO a.s.·interventional·Posted Apr 8, 2014·Updated May 4, 2022

In Brief

A Phase 2 clinical trial evaluating DCVAC/OvCa with Standard of Care, DCVAC/OvCa sequentially chemotherapy, and 1 other intervention for Ovarian Neoplasms and Ovarian Epithelial Cancer. Completed, enrolled 136 participants across 13 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in prolongation of progression free survival (PFS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms, Ovarian Epithelial Cancer
CountriesCzechia, Poland
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 8, 2014
Enrollment StartNov 1, 2013
Primary CompletionNov 1, 2020
Study CompletionNov 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 12.2 years ago

Interventions

DCVAC/OvCa with Standard of Carebiological

DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel

DCVAC/OvCa sequentially chemotherapybiological

DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel

Standard of Caredrug

Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy